Zimmer Biomet Spin-Off’s Share Price Plummets
Executive Summary
The share price for ZimVie, Zimmer Biomet’s spinal and dental spin-off company, dropped following its launch on NASDAQ.
You may also be interested in...
Zimmer Biomet Cuts 3% Of Its Staff To Save $200m A Year
The cuts will cost up to $150m, but the orthopedics company expects to save $200m annually by the end of 2025. The company also announced plans to reduce inventories to prevent excess and obsolescence.
Tornos Ascends To Zimmer Biomet CEO As Hanson Leaves For 3M Spinoff
Ivan Tornos will shift from COO to CEO of Zimmer Biomet now that former CEO Bryan Hanson has accepted the CEO job at 3M’s health care spinoff.
News We’re Watching: ReCor And Medtronic Head To RND Panel, Clearances For Anika And Sequel, ZimVie And Brainlab Partner
This week, the US FDA geared up for a renal denervation panel meeting; a microbiology panel meeting was announced; and a hyaluronic acid patch to promote rotator cuff healing, a novel spiral tampon, and a tibial neuromodulation device to treat incontinence all won FDA clearance.